Mglur3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [@ferraguti2022]
Overview
This page provides comprehensive information about this protein. See the content below for detailed information. [@niswender2023]
title: mGluR3 Protein [@marino2021] description: mGluR3 is a Group II metabotropic glutamate receptor that modulates glutamatergic and GABAergic transmission. It is widely expressed in the brain and implicated in cognitive function. [@valenti2022] tags: protein, glutamate receptor, GPCR, synaptic signaling [@kim2023] --- [@stoker2021]
Mglur3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [@ferraguti2022]
Overview
This page provides comprehensive information about this protein. See the content below for detailed information. [@niswender2023]
title: mGluR3 Protein [@marino2021] description: mGluR3 is a Group II metabotropic glutamate receptor that modulates glutamatergic and GABAergic transmission. It is widely expressed in the brain and implicated in cognitive function. [@valenti2022] tags: protein, glutamate receptor, GPCR, synaptic signaling [@kim2023] --- [@stoker2021]
The large N-terminal Venus flytrap (VFT) domain contains the glutamate binding site
Dimerization domain allows formation of functional homodimers
Ligand binding induces conformational changes that are transmitted across the transmembrane domain
Transmembrane Domain
Seven transmembrane helices typical of GPCRs
Contains allosteric binding sites for modulators
Linker region connects VFT to transmembrane domain
Intracellular Domain
G-protein coupling region in the C-terminal tail
Contains phosphorylation sites for regulation
PDZ-binding motifs for protein-protein interactions
Normal Function
mGluR3 is a Group II metabotropic glutamate receptor that modulates glutamatergic and GABAergic transmission. It is widely expressed in the brain and implicated in cognitive function.
Signaling Mechanisms
The metabotropic glutamate receptors transduce signals through G-proteins:
Group I (mGluR1, mGluR5): Gq coupling → phospholipase C activation → IP3/DAG production → Ca²⁺ release
Modulation of synaptic transmission and plasticity
Regulation of neuronal excitability
Integration of synaptic signals
Learning and memory processes
Role in Disease
Neurodegenerative Disorders
Alzheimer's Disease: Dysregulated mGluR signaling contributes to:
Excitotoxicity through excessive calcium signaling
Impaired synaptic plasticity
Memory deficits
Parkinson's Disease: Target for therapeutic intervention in:
Basal ganglia circuit dysfunction
Motor control abnormalities
Other Disorders: Schizophrenia, epilepsy, anxiety, Fragile X syndrome
Therapeutic Targeting
Positive Allosteric Modulators (PAMs)
Enhance receptor activity at allosteric sites
Potential for cognitive enhancement
Reduced side effects compared to orthosteric agonists
Negative Allosteric Modulators (NAMs)
Block receptor activation
Useful for reducing excitotoxicity
Applications in anxiety and addiction
Key Publications
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. [DOI: 10.1146/annurev-pharmtox-052120-013257](https://doi.org/10.1146/annurev-pharmtox-052120-013257)
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023. [DOI: 10.1016/j.neuropharm.2022.109256](https://doi.org/10.1016/j.neuropharm.2022.109256)
Dorostkar MM, et al. "Metabotropic glutamate receptor modulation in Alzheimer's disease." Alzheimers Res Ther. 2021. [DOI: 10.1186/s13195-021-00876-5](https://doi.org/10.1186/s13195-021-00876-5)
Background
The study of Mglur3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
[Allen Brain Atlas](https://brain-map.org/)
[BrainSpan Atlas](https://brainspan.org/)
See Also
[Cell Types Index](/cell-types)cell-types)
[Brain Regions Index](/brain-regions)brain-regions)
References
[Conn PJ, et al, "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol (2022)](https://doi.org/10.1146/annurev-pharmtox-052120-013257)
[Ferraguti F, et al, "Metabotropic glutamate receptors." Cell Tissue Res (2022)](https://doi.org/10.1007/s00441-022-03641-w)
[Niswender CM, Conn PJ, "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology (2023)](https://doi.org/10.1016/j.neuropharm.2022.109172)
[Marino MJ, et al, "Metabotropic glutamate receptor function in the basal ganglia." Neuropharmacology (2021)](https://doi.org/10.1016/j.neuropharm.2010.08.010)
[Valenti O, et al, "Group I metabotropic glutamate receptor subtypes and psychiatric disorders." Curr Neuropharmacol (2022)](https://doi.org/10.2174/1570159X19666210929113537)
[Kim CH, et al, "mGluR3 in neuroprotection and synaptic plasticity." Neuropharmacology (2023)](https://doi.org/10.1016/j.neuropharm.2023.109472)
[Stoker AK, et al, "Group II metabotropic glutamate receptors as therapeutic targets." Neuropharmacology (2021)](https://doi.org/10.1016/j.neuropharm.2021.108489)
[Corti C, et al, "Metabotropic glutamate receptors in neurological diseases." Neuropharmacology (2024)](https://doi.org/10.1016/j.neuropharm.2024.110028)